An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

The U.S. government announced funding cuts to mRNA vaccine research. What is the impact on American healthcare and biotech?

Patients with rheumatoid arthritis are at an increased risk for venous thromboembolism, regardless of age, sex, BMI, and ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase ...

From clandestine vaccine deals to familial ties with EU-funded ventures, Von der Leyen's leadership has not only eroded ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...